Tetra Releases Full Results of FRAXA-Funded Clinical Trial of PDE4D Inhibitor

Today, Tetra Therapeutics published the full results of its PDE4D trial. The data from this phase 2 clinical trial suggests the PDE4D drug can improve intellectual disability in Fragile X syndrome.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)